03.06.25 -- The Building Blocks For Successful CDMO

Optimize your biopharmaceutical technology transfer by prioritizing clear communication, thorough training, and strategic planning to ensure success.

The development of gene therapy using AAV vectors necessitates the efficient purification of full capsids to ensure therapeutic efficacy and minimize immunogenic risks associated with empty capsids.

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Explore the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.

Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.

Consider several groundbreaking gene editing technologies—TARGATT®, Mad7, and Base Editing—and gain insights into their transformative applications in genetic engineering and therapeutic development.

Partner with us to drive life-changing therapies forward and support families worldwide with innovative supply chain solutions for life sciences.